Identifying Needs and Opportunities to Improve Clinical Outcomes in the Identification, Characterization, and Management of Low-Grade Serous Ovarian Cancer

Target Audience
This activity is designed to meet the educational needs of oncologists, obstetrician/gynecologists, gastroenterologists, and primary care physicians to ensure confidence in the diagnosis, characterization, and management of low-grade serous ovarian cancer, including through enrollment in ongoing clinical trials.

Program Overview
This enduring educational activity will provide insight into evidence-based approaches for clinical and pathological assessment of patients with demonstrated/suspected low-grade serous ovarian cancer (LGSOC). It will also present efficacy and safety considerations for available therapeutic options in the management of LGSOC and the latest evidence regarding novel targeted treatments for this condition, incorporating a detailed look at the clinical rational for RAF, MEK, and FAK inhibition.

Learning Objectives
Upon completion of this activity, participants should be able to:

Recognize the need for improved diagnosis and recognition of the clinical and genomic features of low-grade serous ovarian cancer (LGSOC) to better address disease burden
Review efficacy and safety data for available therapeutic options in the management of LGSOC and needs for novel targeted management
Analyze the latest clinical data informing the safety and efficacy of novel targeted treatments"including RAF, MEK, and FAK"for the clinical management of LGSOCs